Sidedness of the primary tumor on the effect of TAS-102 for refractory metastatic colorectal cancer

被引：0
|
作者：
Ueda, S. [1 ]
Tsuboguchi, Y. [2 ]
Nakatani, Y. [2 ]
Tsuya, A. [3 ]
Nishina, S-I. [4 ]
Akiyoshi, K. [2 ]
Okazaki, S. [5 ]
Tokunaga, S. [2 ]
Daga, H. [2 ]
机构：
[1] Osaka City Gen Hosp, Med Oncol, Nara, Japan
[2] Osaka City Gen Hosp, Med Oncol, Osaka, Japan
[3] Osaka City Gen Hosp, Clin Oncol, Osaka, Japan
[4] Ako Cent Hosp, Med Oncol, Ako City, Japan
[5] Kyoto Med Ctr, Med Oncol, Fushimi Ku, Kyoto, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
472P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The impact of primary tumor sidedness on the effect of regorafenib in refractory metastatic colorectal cancer
    Yoon, Sang Eun
    Hur, Joon Young
    Lee, Su Jin
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Lim, Ho Yeong
    Kang, Won Ki
    Park, Young Suk
    Kim, Seung Tae
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [22] TAS-102 plus bevacizumab in metastatic colorectal cancer Reply
    Pfeiffer, Per
    Moller, Soren
    Winther, Stine Braendegaard
    Qvortrup, Camilla
    [J]. LANCET ONCOLOGY, 2020, 21 (05): : E227 - E227
  • [23] Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Johanna C. Bendell
    Lee S. Rosen
    Robert J. Mayer
    Jonathan W. Goldman
    Jeffrey R. Infante
    Fabio Benedetti
    Donghu Lin
    Hirokazu Mizuguchi
    Christopher Zergebel
    Manish R. Patel
    [J]. Cancer Chemotherapy and Pharmacology, 2016, 77 : 439 - 439
  • [24] Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies
    Sueda, Toshinori
    Sakai, Daisuke
    Kudo, Toshihiro
    Sugiura, Takashi
    Takahashi, Hidekazu
    Haraguchi, Naotsugu
    Nishimura, Junichi
    Hata, Taishi
    Hayashi, Taro
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    Satoh, Taroh
    [J]. ANTICANCER RESEARCH, 2016, 36 (08) : 4299 - 4306
  • [25] A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer
    Su, Guan-Li
    Wang, Yuan-Yuan
    Wang, Jin-Cheng
    Liu, Hao
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (07)
  • [26] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Sugiura, Kiyoaki
    Seo, Yuki
    Takahashi, Takayuki
    Tokura, Hideyuki
    Ito, Yasuhiro
    Tanaka, Motomu
    Kishida, Norihiro
    Nishi, Yusuke
    Onishi, Yoshihiko
    Aoki, Hikaru
    [J]. BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [27] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Kiyoaki Sugiura
    Yuki Seo
    Takayuki Takahashi
    Hideyuki Tokura
    Yasuhiro Ito
    Motomu Tanaka
    Norihiro Kishida
    Yusuke Nishi
    Yoshihiko Onishi
    Hikaru Aoki
    [J]. BMC Gastroenterology, 21
  • [28] A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).
    Cecchini, Michael
    Kortmansky, Jeremy S.
    Lacy, Jill
    Fischbach, Neal A.
    Thumar, Jaykumar Ranchodbhai
    Sabbath, Kert D.
    Gomez, Christina M.
    Sporn, Jonathan
    Stein, Stacey
    Hochster, Howard S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [29] TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer?
    Eng, Cathy
    [J]. LANCET ONCOLOGY, 2020, 21 (03): : 326 - 327
  • [30] Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102
    Hamauchi, Satoshi
    Yamazaki, Kentaro
    Masuishi, Toshiki
    Kito, Yosuke
    Komori, Azusa
    Tsushima, Takahiro
    Narita, Yukiya
    Todaka, Akiko
    Ishihara, Makoto
    Yokota, Tomoya
    Tanaka, Tsutomu
    Machida, Nozomu
    Kadowaki, Shigenori
    Fukutomi, Akira
    Ura, Takashi
    Onozawa, Yusuke
    Ando, Masashi
    Tajika, Masahiro
    Muro, Kei
    Yasui, Hirofumi
    Mori, Keita
    Taniguchi, Hiroya
    [J]. CLINICAL COLORECTAL CANCER, 2017, 16 (01) : 51 - 57
12345